Vallina C, Ramírez L, Torres J, Casañas E, Hernández G, López-Pintor RM. Osteonecrosis of the jaws produced by sunitinib: a systematic review. Med Oral Patol Oral Cir Bucal. 2019 May 1;24 (3):e326-38.
doi:10.4317/medoral.22858
http://dx.doi.org/doi:10.4317/medoral.22858
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
1. Khan AA, Morrison A, Hanley DA, Felsenberg D,
McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of
the jaw: a systematic review and international consensus. J Bone Miner
Res. 2015;30:3-23. |
|
|
|
|
|
2. Bagan J, Peydró A, Calvo J, Leopoldo M, Jiménez
Y, Bagan L. Medication-related osteonecrosis of the jaw associated with
bisphosphonates and denosumab in osteoporosis. Oral Dis. 2016;22:324-9. |
|
|
|
|
|
3. Ramírez L, López-Pintor RM, Casa-as E, Arriba L, Hernández G. New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws. Oral Health Prev Dent. 2015;13:385-93. |
|
|
|
|
|
4. Hoefert S, Eufinger H. Sunitinib may raise the
risk of bisphosphonate-related osteonecrosis of the jaw: presentation of
three cases. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod. 2010;110:463-9. |
|
|
|
|
|
5. Goodman VL, Rock EP, Dagher R, Ramchandani RP,
Abraham S, Gobburu JV, et al. Approval Summary: Sunitinib for the Treatment
of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and
Advanced Renal Cell Carcinoma. Clin Cancer Res. 2007;13:1367-73. |
|
|
|
|
|
6. Beuselinck B, Wolter P, Karadimou A, Elaidi R,
Dumez H, Rogiers A, et al. Concomitant oral tyrosine kinase inhibitors and
bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J
Cancer. 2012;107:1665-71. |
|
|
|
|
|
7. Fleissig Y, Regev E, Lehman H. Sunitinib related
osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral
Radiol. 2012;113:1-3. |
|
|
|
|
|
8. Medicines and Healthcare products Regulatory Agency Gov. UK [sede Web]. UK 2011. [acces 20 mayo de 2018]. Bevacizumab and sunitinib: risk of osteonecrosis of the jaw. Drug Safety Update. 2001;4(6):1. Available in: https://www.gov.uk/drug-safety-update/bevacizumab-and-sunitinib-risk-of-osteonecrosis-of-the-jaw |
|
|
|
|
|
9. Nicolatou-Galitis
O, Migkou M, Psyrri A, Bamias A, Pectasides D, Economopoulos T, et al. Gingival bleeding and jaw bone necrosis in patients with metastatic
renal cell carcinoma receiving sunitinib: report of 2 cases with clinical
implications. Oral Surg Oral Med Oral Pathol Oral
Radiol. 2012;113:234-8. |
|
|
|
|
|
10.
Moher D LA, Tetzlaff J, Altman DG, . The
PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA Statement. . PLoS Med. 2009;6:e1000097. |
|
|
|
|
|
11. Ruggiero
SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper
on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac
Surg. 2014;72:1938-56. |
|
|
|
|
|
12. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). Joanna Briggs Institute Reviewer's Manual. The Joanna Briggs Institute, 2017. Available from https://reviewersmanual.joannabriggs.org/ |
|
|
|
|
|
13. Wells, G. A, Shea, B., O'Connel, D. et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www ohri ca/programs/clinical epidemiology/oxford |
|
|
|
|
|
14. Ashrafi F, Derakhshandeh A, Movahedian B,
Moghaddas A. Osteonecrosis of the Jaws in Patient Received Bisphosphonates
and Sunitinib Separately: A Case Report. J Res Pharm
Pract. 2017;6:182-5. |
|
|
|
|
|
15. Agrillo A, Nastro Siniscalchi E, Facchini A, Filiaci F, Ungari C. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports. Eur Rev Med Pharmacol Sci. 2012;16:952-7. |
|
|
|
|
|
16. Balmor GR, Yarom N, Weitzen R. Drug-induced palate osteonecrosis following nasal surgery. Isr Med Assoc J. 2012;14:193-4. |
|
|
|
|
|
17. Bozas G, Roy A, Ramasamy V, Maraveyas A.
Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient
with metastatic renal cancer treated with sunitinib. Onkologie. 2010;33:321-3. |
|
|
|
|
|
18. Koch FP, Walter C, Hansen T, Jäger E, Wagner W.
Osteonecrosis of the jaw related to sunitinib. J Oral Maxillofac
Surg. 2011;15:63-6. |
|
|
|
|
|
19. Brunello A, Saia G, Bedogni A, Scaglione D,
Basso U. Worsening of osteonecrosis of the jaw during treatment with
sunitinib in a patient with metastatic renal cell carcinoma. Bone. 2009;44:173-5. |
|
|
|
|
|
20. Mahedi Mohamed AH, Nielsen CE, Schiodt M.
Medication related osteonecrosis of the jaws associated with targeted therapy
as monotherapy and in combination with antiresorptives. A report of 7 cases
from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:157-63. |
|
|
|
|
|
21.
Fusco V, Porta C, Saia G, Paglino C, Bettini G, Scoletta M, et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer
treated with bisphosphonates and targeted agents: Results of an Italian
multicenter study and review of the literature. Clin Genitourin
Cancer. 2015;13:287-94. |
|
|
|
|
|
22. Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M,
Donskov F. Combination of zoledronic Acid and targeted therapy is active but
may induce osteonecrosis of the jaw in patients with metastatic renal cell
carcinoma. J
Oral Maxillofac Surg. 2013;71:1532-40. |
|
|
|
|
|
23. Christodoulou
C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates and antiangiogenic factors induces
osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology.2009;76:209-1. |
|
|
|
|
|
24. McKay RR, Lin X, Perkins JJ, Heng DY, Simantov
R, Choueiri TK. Prognostic significance of bone metastases and bisphosphonate
therapy in patients with renal cell carcinoma. Eur Urol. 2014;66:502-9. |
|
|
|
|
|
25. Ripamonti CI, Lucchesi M, Giusti R. Prevention
and management of osteonecrosis of the jaw secondary to bone-targeted therapy
in patients with kidney cancer. Curr Opin Support Palliat
Care. 2016;10:273-80. |
|
|
|
|
|
26. Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K, Troeltzsch M. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc. 2012;78:85. |
|
|
|
|
|
27.
Martins AS, Correia JA, Salvado F, Caldas C, Santos N, Capelo A, et al. Relevant factors for treatment outcome and time to healing in
medication related osteonecrosis of the jaws - A retrospective cohort
study. J
Craniomaxillofac Surg. 2017;45:1736-42. |
|
|
|
|
|
28. Marx RE, Sawatari Y, Fortin M, Broumand V.
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the
jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac
Surg. 2005;63:1567-75. |
|